CYP19A1 and Alzheimer disease: The enhancement of testosterone levels in the late stage of AD pathology as well as the upregulation of aromatase and 17β-HDS type 1 (which can also convert estrone to E2) to enhance E2 synthesis could be viewed as part of a compensatory neuroprotective mechanism.